BR112023019795A2 - Composições nasais compreendendo alcaftadina - Google Patents
Composições nasais compreendendo alcaftadinaInfo
- Publication number
- BR112023019795A2 BR112023019795A2 BR112023019795A BR112023019795A BR112023019795A2 BR 112023019795 A2 BR112023019795 A2 BR 112023019795A2 BR 112023019795 A BR112023019795 A BR 112023019795A BR 112023019795 A BR112023019795 A BR 112023019795A BR 112023019795 A2 BR112023019795 A2 BR 112023019795A2
- Authority
- BR
- Brazil
- Prior art keywords
- alcaftadine
- nasal
- nasal compositions
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202121015680 | 2021-04-01 | ||
| PCT/IB2021/055221 WO2022208146A1 (en) | 2021-04-01 | 2021-06-14 | Nasal compositions comprising alcaftadine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023019795A2 true BR112023019795A2 (pt) | 2023-11-07 |
Family
ID=76523258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023019795A BR112023019795A2 (pt) | 2021-04-01 | 2021-06-14 | Composições nasais compreendendo alcaftadina |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US20240173331A1 (https=) |
| EP (1) | EP4312973A1 (https=) |
| JP (1) | JP2024512121A (https=) |
| KR (1) | KR20230163413A (https=) |
| CN (1) | CN117120029A (https=) |
| AU (1) | AU2021437358A1 (https=) |
| BR (1) | BR112023019795A2 (https=) |
| CA (1) | CA3213156A1 (https=) |
| CL (1) | CL2023002871A1 (https=) |
| MX (1) | MX2023011546A (https=) |
| WO (1) | WO2022208146A1 (https=) |
| ZA (1) | ZA202308388B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240173331A1 (en) * | 2021-04-01 | 2024-05-30 | Alkem Laboratories Limited | Nasal compositions comprising alcaftadine |
| CN114504037B (zh) * | 2022-01-14 | 2024-12-03 | 云南中茶茶业有限公司 | 一种茶叶发酵瓶用出瓶机 |
| US11992493B1 (en) * | 2022-10-25 | 2024-05-28 | Liangdan Sun | Use of compound or pharmaceutical derivative thereof in inhibiting CaMK2G protein activity |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3877904D1 (de) | 1987-11-13 | 1993-03-11 | Asta Pharma Ag | Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge. |
| IL101850A (en) | 1991-06-13 | 1996-01-31 | Janssen Pharmaceutica Nv | 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them |
| US7666876B2 (en) | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| PL1919450T3 (pl) | 2005-09-01 | 2014-11-28 | Meda Ab | Kompozycja liposomowa zawierająca lek przeciwhistaminowy i kortykosteroid oraz jej zastosowanie do wytwarzania leku do leczenia nieżytu nosa i chorób spokrewnionych |
| BRPI0710085B8 (pt) * | 2006-03-31 | 2021-05-25 | Vistakon Pharmaceutical Llc | composições oftálmicas e seus kits |
| CA2840731A1 (en) * | 2011-06-29 | 2013-01-03 | Allergan, Inc. | Alcaftadine for use in the treatment of urticaria |
| CN102283849A (zh) | 2011-06-29 | 2011-12-21 | 北京阜康仁生物制药科技有限公司 | 一种含有阿卡他定的药物组合物 |
| WO2019022225A1 (ja) | 2017-07-28 | 2019-01-31 | 参天製薬株式会社 | アルカフタジン又はその塩を含有する水性医薬組成物 |
| WO2021255622A1 (en) * | 2020-06-15 | 2021-12-23 | Alkem Laboratories Limited | Combination of alcaftadine and a corticosteroid |
| US20240173331A1 (en) * | 2021-04-01 | 2024-05-30 | Alkem Laboratories Limited | Nasal compositions comprising alcaftadine |
-
2021
- 2021-06-14 US US18/549,916 patent/US20240173331A1/en active Pending
- 2021-06-14 BR BR112023019795A patent/BR112023019795A2/pt unknown
- 2021-06-14 CA CA3213156A patent/CA3213156A1/en active Pending
- 2021-06-14 JP JP2023560146A patent/JP2024512121A/ja active Pending
- 2021-06-14 EP EP21733563.7A patent/EP4312973A1/en active Pending
- 2021-06-14 WO PCT/IB2021/055221 patent/WO2022208146A1/en not_active Ceased
- 2021-06-14 CN CN202180096503.1A patent/CN117120029A/zh active Pending
- 2021-06-14 KR KR1020237033154A patent/KR20230163413A/ko active Pending
- 2021-06-14 MX MX2023011546A patent/MX2023011546A/es unknown
- 2021-06-14 AU AU2021437358A patent/AU2021437358A1/en active Pending
-
2023
- 2023-08-30 ZA ZA2023/08388A patent/ZA202308388B/en unknown
- 2023-09-26 CL CL2023002871A patent/CL2023002871A1/es unknown
-
2024
- 2024-11-11 US US18/943,124 patent/US20250064825A1/en not_active Abandoned
- 2024-11-11 US US18/943,210 patent/US12274702B2/en active Active
- 2024-11-11 US US18/943,165 patent/US20250064826A1/en not_active Abandoned
- 2024-11-11 US US18/943,269 patent/US20250064828A1/en not_active Abandoned
-
2025
- 2025-03-21 US US19/087,084 patent/US20260007682A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250064825A1 (en) | 2025-02-27 |
| KR20230163413A (ko) | 2023-11-30 |
| MX2023011546A (es) | 2023-10-06 |
| US12274702B2 (en) | 2025-04-15 |
| US20240173331A1 (en) | 2024-05-30 |
| US20250064827A1 (en) | 2025-02-27 |
| EP4312973A1 (en) | 2024-02-07 |
| US20260007682A1 (en) | 2026-01-08 |
| US20250064826A1 (en) | 2025-02-27 |
| WO2022208146A1 (en) | 2022-10-06 |
| JP2024512121A (ja) | 2024-03-18 |
| CA3213156A1 (en) | 2022-10-06 |
| US20250064828A1 (en) | 2025-02-27 |
| AU2021437358A1 (en) | 2023-09-14 |
| ZA202308388B (en) | 2025-11-26 |
| CN117120029A (zh) | 2023-11-24 |
| CL2023002871A1 (es) | 2024-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022024840A2 (pt) | Combinação de alcaftadina e um corticosteroide | |
| BR112023019795A2 (pt) | Composições nasais compreendendo alcaftadina | |
| CL2022002481A1 (es) | Compuestos antivirales y métodos para la administración de los mismos | |
| ECSP19070369A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112014024672A8 (pt) | Composições farmacêuticas para terapia de combinação | |
| BR112018015273A2 (pt) | derivados de benzimidazol como moduladores de ror-gama | |
| ECSP19070413A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112023018472A2 (pt) | Composições de psilocibina, métodos de produção e métodos de uso das mesmas | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CO2019013042A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CR20180493A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112022009805A2 (pt) | Derivados de piridopirimidinona como antagonistas de ahr | |
| BR112021021284A2 (pt) | Composto, composição farmacêutica, e, métodos para o tratamento ou profilaxia de doenças inflamatórias da pele, doenças respiratórias, doenças gastrointestinais, doenças oculares, cânceres, doenças reumáticas, doenças desmielinizantes e doenças fibróticas e de inibição da atividade de proteínas de bromodomínio e domínio terminal extra | |
| EA202191239A1 (ru) | Соединения и их применение для лечения дефицита 1-антитрипсина | |
| MX2021004331A (es) | Composiciones estables de semaglutida y usos de las mismas. | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| BR112021025701A2 (pt) | Formulações e métodos de parasiticida de isoxazolina para tratar blefarite | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| BR112018072177A2 (pt) | composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta | |
| MX389596B (es) | Composiciones y métodos para el tratamiento de enfermedades de la mucosa nasal y paranasal con agonistas del receptor de acetilcolina de tipo nicotínico. | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| MX2024000043A (es) | Compuestos inhibidores de la caspasa-2. |